Search research articles
Contact Us
Filters
Showing results (201-210 of 222) with videos related to
Page
of 23
Sort By:
Plos Medicine
|
June 22, 2012
Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial
Shahin Lockman, Michael Hughes, Fred Sawe, et al.
Cancer Cell
|
October 12, 2016
Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer
Nidal E Muvarak, Khadiza Chowdhury, Limin Xia, et al.
The Lancet. HIV
|
October 2, 2015
Effect of the CCR5 antagonist maraviroc on the occurrence of immune reconstitution inflammatory syndrome in HIV (CADIRIS): a double-blind, randomised, placebo-controlled trial
Juan G Sierra-Madero, Susan S Ellenberg, Mohammed S Rassool, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 14, 2026
Antiretroviral Activity, Pharmacokinetics, and Safety of MK-8527, an Oral Nucleoside Reverse Transcriptase Translocation Inhibitor, in Adults Living With HIV-1 Who Had Not Previously Taken Antiretroviral Agents: Results From Two Open-Label, Phase 1 Studies
Russ P Carstens, Yash Kapoor, Ryan C Vargo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 13, 2024
Effectiveness of Double-Dose Dolutegravir in People Receiving Rifampin-based Tuberculosis Treatment: An Observational, Cohort Study of People With HIV From 6 Countries
N Sarita Shah, Cissy Kityo, Michael D Hughes, et al.
The Lancet. Respiratory Medicine
|
November 17, 2019
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial
Conor D Tweed, Rodney Dawson, Divan A Burger, et al.
Cancer Research
|
September 16, 2010
Cancer-related epigenome changes associated with reprogramming to induced pluripotent stem cells
Joyce E Ohm, Prashant Mali, Leander Van Neste, et al.
The Lancet. HIV
|
September 19, 2017
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial
Pedro Cahn, Richard Kaplan, Paul E Sax, et al.
The Lancet. Global Health
|
January 31, 2025
24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation
Sedona Sweeney, Yoko V Laurence, Catherine Berry, et al.
Lancet (London, England)
|
November 11, 2022
Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial
Ruth L Goodall, Sarah K Meredith, Andrew J Nunn, et al.
Page
of 23
Search research articles
Search
Showing results (201-210 of 222) with videos related to
Sort By:
Page
of 23
Plos Medicine
|
June 22, 2012
Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial
Shahin Lockman, Michael Hughes, Fred Sawe, et al.
Cancer Cell
|
October 12, 2016
Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer
Nidal E Muvarak, Khadiza Chowdhury, Limin Xia, et al.
The Lancet. HIV
|
October 2, 2015
Effect of the CCR5 antagonist maraviroc on the occurrence of immune reconstitution inflammatory syndrome in HIV (CADIRIS): a double-blind, randomised, placebo-controlled trial
Juan G Sierra-Madero, Susan S Ellenberg, Mohammed S Rassool, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 14, 2026
Antiretroviral Activity, Pharmacokinetics, and Safety of MK-8527, an Oral Nucleoside Reverse Transcriptase Translocation Inhibitor, in Adults Living With HIV-1 Who Had Not Previously Taken Antiretroviral Agents: Results From Two Open-Label, Phase 1 Studies
Russ P Carstens, Yash Kapoor, Ryan C Vargo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 13, 2024
Effectiveness of Double-Dose Dolutegravir in People Receiving Rifampin-based Tuberculosis Treatment: An Observational, Cohort Study of People With HIV From 6 Countries
N Sarita Shah, Cissy Kityo, Michael D Hughes, et al.
The Lancet. Respiratory Medicine
|
November 17, 2019
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial
Conor D Tweed, Rodney Dawson, Divan A Burger, et al.
Cancer Research
|
September 16, 2010
Cancer-related epigenome changes associated with reprogramming to induced pluripotent stem cells
Joyce E Ohm, Prashant Mali, Leander Van Neste, et al.
The Lancet. HIV
|
September 19, 2017
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial
Pedro Cahn, Richard Kaplan, Paul E Sax, et al.
The Lancet. Global Health
|
January 31, 2025
24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation
Sedona Sweeney, Yoko V Laurence, Catherine Berry, et al.
Lancet (London, England)
|
November 11, 2022
Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial
Ruth L Goodall, Sarah K Meredith, Andrew J Nunn, et al.
Page
of 23